In the United States, an estimated 1.2 million people are living with chronic hepatitis B virus (HBV) infection, and 3.2 are living with chronic hepatitis C virus (HCV) infection. Many do not know they are infected. Each year an estimated 43,000 Americans become newly infected with HBV, and 17,000 with HCV. Infection with both HBV and HCV are also a global public health challenge that causes significant morbidity and mortality, with the burden of disease especially high in less-developed countries, although prevalence data for these two forms of viral hepatitis is only adequately monitored in Asia, Europe, and Latin America.

There exist significant challenges to diagnosing and linking to treatment large numbers of HBV- and HCV-infected patients who are unaware of their serostatus and thus are not on either anti-HBV or anti-HCV treatment. Beyond diagnosis, however, there are bottlenecks preventing expanded access to HBV and HCV care, not the least of which is caused by the fact patients are currently referred for care to hepatologists and gastroenterologists, of whom there are insufficient numbers in the United States and, indeed, globally to meet treatment demand. This bottleneck must be addressed in light of advances in HBV and HCV treatment, which requires an expanded number of clinicians from multiple disciplines to deliver HBV and HCV care.

Hosted at the historic New York Academy of Medicine, this two-day conference will serve as a forum for the presentation and discussion of state-of-the-science research on HBV and HCV infection, and current clinical management perspectives in practicum. The conference’s aim is to ensure this dialogue translates into evidence-based implementation of approaches for real world clinical and community settings.

Target Audience 

This educational conference has been designed for gastroenterologists, hepatologists, and infectious disease (ID) and non-ID-specialized physicians, nurses, and pharmacists involved (or soon to be involved) in the diagnosis and active management of patients with HBV or HCV infection.


  • Describe strategies for viral hepatitis diagnosis and linkages to evidence-based care and treatment
  • Define the characteristics and recommended use of approved agents for the management of viral hepatitis
  • Identify treatment options for patients who present with viral hepatitis, including interventions to promote treatment success
  • Discuss the management of complications due to viral hepatitis, its treatment, and/or comorbidities
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert